Amylyx Pharmaceuticals, Inc. (AMLX)
After hours:
| Previous Close | 2.0300 |
| Open | 2.0400 |
| Bid | 1.9700 x 800 |
| Ask | 2.0200 x 300 |
| Day's Range | 1.9400 - 2.0497 |
| 52 Week Range | 1.7000 - 30.5000 |
| Volume | |
| Avg. Volume | 3,539,096 |
| Market Cap | 135.332M |
| Beta (5Y Monthly) | -0.93 |
| PE Ratio (TTM) | 2.84 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
CAMBRIDGE, Mass., May 02, 2024--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") will report its first quarter 2024 financial results on Thursday, May 9, 2024. Amylyx’ senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss the financial results and other company updates.
- Business Wire
Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
CAMBRIDGE, Mass., April 10, 2024--Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial
- Business Wire
Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024
CAMBRIDGE, Mass., April 08, 2024--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced the Company will host a virtual webcast with management and Fumihiko Urano, MD, PhD, Principal Investigator of the HELIOS clinical trial and the Samuel E. Schechter Professor of Medicine in the Division of Endocrinology, Metabolism & Lipid Research at Washington University School of Medicine in St. Louis to discuss interim data from HELIOS, a Phase 2 trial of AMX0035 for the
